NBCD is dedicated to clinical drug development in Osteoarthritis. We specialize in design and execution of clinical trials within both pain and DMOAD compounds for osteoarthritis. We are experts in placebo response mitigation and selecting the right patients. Our background makes us experts in precision medicine using unique biomarker technologies. We support our biotech and pharmaceutical clients advance their osteoarthritis compounds through all clinical development phases.
NBCD has more than 25 years’ experience in biomarker development and clinical trials and has particularly acquired extensive expertise in rheumatology. Combining our experience in preclinical and clinical research enables us to help provide a faster and smarter detection of signals of the potential clinical viability of drug candidates.
We tailor our unique solutions to our clients’ needs. As a privately owned, specialized company we are able to make decisions swiftly, leverage cross-functional synergies and quickly adapt the organization to best accommodate current and future needs.
Our approach and mindset are highly scientific and we take pride in frequently publishing our results in leading journals worldwide. In fact, on average we publish around 50 articles each year.
How It All Began
The first biochemical marker developed by Nordic Bioscience was serum osteocalcin, a marker of bone formation. This initial biomarker was followed by the development of a large spectrum of novel biomarkers in several different diseases.
Vision, Mission and Values
We want to develop targeted treatments faster, better and cheaper with a more favorable risk-benefit ratio for patients and payers.
Read about Nordic Bioscience and the latest research, achievements and results.